Last year was a pivotal one for mRNA therapeutics. What once were niche proof-of-concept workflows evolved into robust, regulatory ready platforms.
Three trends stood out. First, LC-based integrity and purity assays that had been optimised for long RNA analytes became widely adopted, offering faster, higher-resolution sizing and purity checks.
Second, LC–MS integration matured, enabling sequence-level and impurity profiling for both intact and digested mRNA.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.